First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

  1. Arranz, R.
  2. García-Noblejas, A.
  3. Grande, C.
  4. Cannata-Ortiz, J.
  5. Sánchez, J.J.
  6. García-Marco, J.-A.
  7. Aláez, C.
  8. Pérez-Calvo, J.
  9. Martínez-Sánchez, P.
  10. Sánchez-González, B.
  11. Canales, M.-A.
  12. Conde, E.
  13. Martín, A.
  14. Arranz, E.
  15. Terol, M.-J.
  16. Salar, A.
  17. Caballero, D.
Aldizkaria:
Haematologica

ISSN: 0390-6078,  1592-8721

Argitalpen urtea: 2013

Alea: 98

Zenbakia: 10

Orrialdeak: 1563-1570

Mota: Artikulua

DOI: 10.3324/HAEMATOL.2013.088377 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus